Poster presentations to take place at ISCTM on Friday October 10th and at ECNP on Saturday October 11th in Amsterdam, the Netherlands.
First Published: 13 October, 2025
Cumulus Neuroscience will present data at two international conferences in Amsterdam, the Netherlands in October: the International Society for CNS Clinical Trials Methodology (ISCTM) Autumn Conference, and the 38th European Neuropsychopharmacology conference.
"The NeuLogiq Platform was purpose-built in collaboration with 10 top biopharma companies to generate objective clinical quality data in CNS Clinical Trials, with an initial focus in Alzheimer’s dementia" said Brian Murphy, PhD, Co-Founder and Chief Scientific Officer of Cumulus. "We’re excited to present data at these conferences that also show the validity of multimodal digital biomarkers in neuropsychiatry, whether collected in the clinic or in the home. Additionally, we show how these biomarkers’ superior sensitivity to progression can lead to streamlined study designs."
The posters were accepted by the ISCTM and ECNP Scientific Program Committees for presentation at the meetings and online. Live poster presentation details are as follows:
International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference
Title: Streamlining CNS clinical research with digital endpoints – the trade-off between shorter versus smaller trial designs
Date & Time: Friday 10th October 2025, 17:45-19:15 PM CEST
Session: Formal poster session
European College of Neuropsychopharmacology (ECNP)
Poster 1
Title: Scalable Digital Endpoints Improve Sensitivity to Cognitive Change and Can Drive Efficiencies in CNS Clinical Trials
Date & Time: Saturday, October 11, 2025: 12:00 – 13:25
Poster Number: PS01-0068
Session: Poster Session
Poster 2, in partnership with Delix Therapeutics:
Title: Deploying User-Friendly Portable EEG to Measure Response to a Novel Antidepressant with Resting and Task-Driven Neurophysiological Endpoints
Date & Time: Saturday, October 11, 2025: 19:00 – 19:30
Poster Number: EP02-0103
Session: Online
Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit www.cumulusneuro.com.
About Delix Therapeutics
Delix Therapeutics is a clinical-stage neuroscience company focused on harnessing the power of novel neuroplasticity-promoting therapeutics to better treat patients struggling with difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds are small molecules capable of rapidly inducing structural and functional neural changes in targeted areas of the brain. Through its novel Neuroplastogen Platform, Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and rapidly advancing through preclinical and clinical development to bring patients FDA-approved medicines that are intended to serve several unmet needs and enhance the psychiatric treatment paradigm for patients and providers.